News
ABBV-706 is an ADC targeting SEZ6 developed by AbbVie. It is linked to a topoisomerase 1 inhibitor (TOP1i) via a ...
Pedro Valencia, VP, asset strategy leadership, oncology, AbbVie, discusses how early data from ABBV-706 shows up to 50% ...
Small cell lung cancer is aggressive and spreads quickly. There are many options for treatment, depending on the type and stage of SCLC.
Pedro Valencia, VP, asset strategy leadership, oncology, outlines how unmet need, treatment stagnation, and pipeline innovation shape the company’s approach to solid tumor oncology following key data ...
New Report Highlights Emerging Leaders Advancing Next-generation Radiopharmaceuticals, Reshaping Cancer Care Through Targeted Innovation and Strategic Growth LONDON, June 16, 2025 /PRNewswire/ ...
CNW/ -- (NYSE:CLVT), a leading global provider of transformative intelligence, today announced the release of a new Companies to Watch ...
DLL3 is an antigen overexpressed in many neuroendocrine tumors, such as SCLC, and is often associated with poor clinical outcomes. ZL-1310 comprises a humanized anti-DLL3 monoclonal antibody connected ...
Additionally, two-thirds of all SCLC patients are diagnosed at extensive stage 3. DLL3 is an antigen overexpressed in many neuroendocrine tumors, such as SCLC, and is often associated with poor ...
Zai Lab Presents Positive Phase 1 Data for ZL-1310, a DLL3-Targeted ADC, Demonstrating Robust Anti-Tumor Activity and Safety in Patients with Extensive-Stage Small Cell Lung Cancer at 2025 ASCO ...
IDEAYA is targeting to evaluate IDE849 clinically in a multi-site global clinical trial as a monotherapy agent in SCLC, NETs and multiple DLL3 upregulated solid tumor types, and to evaluate IDE849 ...
Proposed mechanisms of resistance to immune checkpoint blockade in SCLC include downregulation of major histocompatibility complex (MHC) class I molecules, poor tumor infiltration by T cells, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results